BIOMAT Database Logo BIOMAT Database Logo

Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. 1998

M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Department of Biochemistry, University of Toronto, Ontario, Canada. margaret.rand@sickkids.on.ca

Elevated levels of lipoprotein(a) [Lp(a)] are correlated with an increased risk of atherosclerotic disease. We examined the effect of recombinant apolipoprotein(a) [r-apo(a)] and Lp(a) on responses of washed human platelets, prelabeled in the dense granules with [14C]serotonin and suspended in Tyrode's solution, to ADP and the thrombin receptor-activating peptide SFLLRN. No effect of the 17 kringle (K), 12K, or 6K r-apo(a) derivatives (at concentrations of 0.35 and 0.7 micromol/L) or Lp(a) (up to 0.1 micromol/L) on primary ADP-induced platelet aggregation was observed. In contrast, weak platelet responses stimulated by 7.5 micromol/L SFLLRN were significantly enhanced by the r-apo(a) derivatives; eg, 0.7 micromol/L 17K r-apo(a) increased aggregation from 15+/-4% to 58+/-6%, release of [14C]serotonin from 9+/-3% to 36+/-6%, and formation of thromboxane A2, measured as its stable metabolite thromboxane B2, from 7+/-1 to 29+/-5 ng/10(9) platelets (n=3; P<0.04 to 0.015). Significant enhancement of aggregation and release of granule contents was observed at a concentration of 17K r-apo(a) as low as 0.175 micromol/L. Purified Lp(a) (0.25 to 0.1 micromol/L) also enhanced SFLLRN-induced aggregation and release in a dose-dependent manner. Although plasminogen (0.7 and 1.5 micromol/L) and low density lipoprotein (0.025 to 0.1 micromol/L) both exhibited potentiating effects on SFLLRN-mediated platelet aggregation, the magnitude of the responses was less than that observed with either the r-apo(a) derivatives or Lp(a). The enhanced responses of platelets via the protease-activated receptor- thrombin receptor in the presence of Lp(a) may contribute to the increased risk of thromboembolic complications of atherosclerosis associated with this lipoprotein.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D001054 Apolipoproteins A Structural proteins of the alpha-lipoproteins (HIGH DENSITY LIPOPROTEINS), including APOLIPOPROTEIN A-I and APOLIPOPROTEIN A-II. They can modulate the activity of LECITHIN CHOLESTEROL ACYLTRANSFERASE. These apolipoproteins are low in atherosclerotic patients. They are either absent or present in extremely low plasma concentration in TANGIER DISEASE. Apo-A,ApoA

Related Publications

M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation.
January 2000, The Journal of laboratory and clinical medicine,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
April 1997, Thrombosis and haemostasis,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Effects of thrombin and thrombin peptide activating receptor (SFLLRN) on proteoglycan synthesis and distribution in human endothelial cells.
December 1994, Biochemical and biophysical research communications,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Effects of thrombin and the thrombin receptor activating peptide, SFLLRN, on redistribution of platelet alpha-granule contents are similar and independent of the extent of thromboxane formation.
February 1995, Experimental and molecular pathology,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin.
December 1993, Thrombosis and haemostasis,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Thrombin receptor activating peptide does not stimulate platelet procoagulant activity.
July 1994, Biochemical and biophysical research communications,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation.
May 2001, Journal of cardiovascular pharmacology,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Thrombin receptor-activating peptide sensitizes the human endothelial thrombin receptor.
January 1995, The American journal of physiology,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Species differences in platelet responses to thrombin and SFLLRN. receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases.
June 1995, Thrombosis research,
M L Rand, and W Sangrar, and M A Hancock, and D M Taylor, and S M Marcovina, and M A Packham, and M L Koschinsky
Relaxant and contractile responses of porcine pulmonary arteries to a thrombin receptor activating peptide (TRAP).
April 1994, Naunyn-Schmiedeberg's archives of pharmacology,
Copied contents to your clipboard!